CAL
ACRS icon

Capital Advisors Ltd’s Aclaris Therapeutics ACRS Stock Holding History

Capital Advisors Ltd’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Hold
454
– – ﹤0.01% 1088
2026
Q1 		$2K Hold
454
– – ﹤0.01% 1067
2025
Q4 		$1K Hold
454
– – ﹤0.01% 1128
2025
Q3 		$1K Hold
454
– – ﹤0.01% 1123
2025
Q2 		$1K Hold
454
– – ﹤0.01% 1123
2025
Q1 		$1K Hold
454
– – ﹤0.01% 1112
2024
Q4 		$1K Hold
454
– – ﹤0.01% 1133
2024
Q3 		$1K Hold
454
– – ﹤0.01% 1127
2024
Q2 		$0 Buy
+454
New +$533 ﹤0.01% 1344

Other funds holding ACRS

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Capital Advisors Ltd's ACRS Position: Q2 2026 in Review

Capital Advisors Ltd held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 454 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1088.

Capital Advisors Ltd first reported a position in ACRS in Q2 2024 and has held it in 9 quarters since. 7 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Capital Advisors Ltd held 454 shares of Aclaris Therapeutics worth $2K as of Q2 2026.
  • Capital Advisors Ltd left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1088 holding.
  • Capital Advisors Ltd first reported a position in Aclaris Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 7 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.